Biopure Company Analysis

If you order your custom term paper from our custom writing service you will receive a perfectly written assignment on Biopure Company Analysis. What we need from you is to provide us with your detailed paper instructions for our experienced writers to follow all of your specific writing requirements. Specify your order details, state the exact number of pages required and our custom writing professionals will deliver the best quality Biopure Company Analysis paper right on time.

Out staff of freelance writers includes over 120 experts proficient in Biopure Company Analysis, therefore you can rest assured that your assignment will be handled by only top rated specialists. Order your Biopure Company Analysis paper at affordable prices with Live Paper Help!

Company Analysis ?BPC is a manufacturer of blood substitutes, specifically Hemopure (Hp) for humans and Oxyglobin (Og) for the veterinary (mainly canine) market. Although Hp is expected (without guarantee) to receive FDA approval by the end of 1, Og received approval for general use in 17. BPC has already invested $00 million on product development and manufacturing facilities for the two products, and recently received $50 million in Venture Capital funding; thus, it has little if any short-term financial constraints. The company’s plant capacity is 00,000 units of Og, or 150,000 units of Hp. There is considerable flexibility in switching from the manufacturing of one product to another, and BPC can manufacture both at the same time (given the resulting linear function from the capacity figures above). These capacity numbers, however, are limited in comparison to the larger potential market. Given its competitors in the human blood market, BPC would be place third among three competitors, whereas in the canine market, it would have a monopoly for a minimum of two years. As such, BPC would likely be a price taker in the human blood supply market, whereas it would be a price setter in the canine market, allowing it to maximize profits by charging the highest possible price given its current capacity. An undersupplied marketplace for both humans and canines will allow for sufficiently elevated prices (Exhibit ).

In performing a VRIO analysis of BPC (Exhibit 4), one sees the unique use of bovine precursors and product differentiation of Og as sustainable competitive advantages. The unique raw material provides a variable cost advantage. As well, the seasonal variation in human blood supply would not affect BPC’s supply of raw materials as it would for its competitors. Hp, while a valuable resource for BPC, cannot be considered a sustainable competitive advantage due to its two competitors. Its lower-cost production process allows BPC to position itself as a lower-cost producer. However, this would be difficult to take advantage of as it will have to take the price set by the market leader. While this would still provide for higher margins, the percentage gain would be minimal compared to the otherwise high margins.

The company is seriously interested in pursuing an IPO, which could be greatly enhanced with a product in the marketplace generating revenue, an established customer base and experience in producing large amounts of blood substitute in its facilities. As well, the revenues from an Og launch could generate additional funds for the future launch of Hp.






Please note that this sample paper on Biopure Company Analysis is for your review only. In order to eliminate any of the plagiarism issues, it is highly recommended that you do not use it for you own writing purposes. In case you experience difficulties with writing a well structured and accurately composed paper on Biopure Company Analysis, we are here to assist you. Your cheap custom college paper on Biopure Company Analysis will be written from scratch, so you do not have to worry about its originality.

Order your authentic assignment from Live Paper Help and you will be amazed at how easy it is to complete a quality custom paper within the shortest time possible!